Anifrolumab, a relatively emerging monoclonal protein, is sparking considerable excitement within the medical community as a viable option for various inflammatory conditions. This unique agent targets the interferon https://socialmediainuk.com/story27123834/anifrolumab-a-promising-treatment-for-immune-mediated-illnesses